BORTEZOMIB | N206927 | DR REDDYS LABORATORIES LTD
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | University of Arkansas | 50 | 2017-07-01 → 2028-10 | |
| Phase 3 | Active | Janssen Research & Development, LLC | 838 | 2024-01-22 → 2028-12-31 | |
| Phase 2 | Active | National Cancer Institute (NCI) | 75 | 2004-10-28 → 2028-10-01 | |
| Phase 1/2 | Active | St. Jude Children's Research Hospital | 50 | 2016-01-29 → 2031-10 | |
| Phase 2 | Active | National Cancer Institute (NCI) | 58 | 2024-07-23 → 2027-09-23 | |
| Phase 2 | Active | Janssen Research & Development, LLC | 151 | 2022-03-01 → 2026-11-23 | |
| Phase 3 | Active | Janssen Research & Development, LLC | 587 | 2021-10-14 → 2028-09-15 | |
| Phase 1 | Active | Janssen Research & Development, LLC | 140 | 2021-03-12 → 2027-10-13 | |
| Phase 3 | Active | Janssen Research & Development, LLC | 419 | 2020-06-12 → 2027-03-31 | |
| Phase 2 | Active | University of Arkansas | 160 | 2009-03 → 2027-12 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
21 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Mar 1, 2022 | SUPPL -2 | View Letter (PDF) |
| Oct 7, 2019 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.